ADMA Biologics Inc (OQ:ADMA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: C/O Adma Biologics
Inc., 465 State Route 17
Tel: N/A
IR: See website
Key People
Steven A. Elms
Chairman of the Board
Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Brian Lenz
Chief Financial Officer, Executive Vice President
James Mond
Chief Scientific and Medical Officer
Business Overview
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Financial Overview
For the three months ended 31 March 2019, ADMA Biologics Inc revenues decreased 13% to $3.5M. Net loss decreased 27% to $13.1M. Revenues reflect ADMA Bio Manufacturing segment decrease of 19% to $1.3M, Plasma Collection Center segment decrease of 8% to $2.1M. Lower net loss reflects ADMA Bio Manufacturing segment loss decrease of 99% to $170K, Corporate segment loss decrease of 54% to $1.3M.
Employees: 318 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $250.00M as of Mar 31, 2019
Annual revenue (TTM): $16.47M as of Mar 31, 2019
EBITDA (TTM): -$53.54M as of Mar 31, 2019
Net annual income (TTM): -$60.99M as of Mar 31, 2019
Free cash flow (TTM): -$62.19M as of Mar 31, 2019
Net Debt Last Fiscal Year: $40.90M as of Mar 31, 2019
Shares outstanding: 57,603,068 as of May 16, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization